Annual report
4523.TEDINET S100TM93
Period2023-04-01 → 2024-03-31
Filed2024-06-14
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥741.8bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥744.4bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥756.2bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥645.9bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥695.6bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥53.4bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥40.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥61.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥45.0bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥42.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥55.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥48.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥41.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥121.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥43.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥56.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥45.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥42.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥122.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss IFRS (5-year summary) |
| Total assets | ¥1.39T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.26T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.24T | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.09T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.06T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥494.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥440.8bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥899.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥822.6bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥771.5bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥875.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥800.0bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥748.8bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥701.6bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥678.1bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥304.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥267.4bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥309.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥248.7bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥254.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥56.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥73.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥102.8bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥25.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥22.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥28.8bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥36.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥27.6bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥22.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥24.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥49.0bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥55.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥103.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥147.86 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥193.31 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥167.27 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥146.34 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥425.01 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥147.86 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥193.31 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥167.25 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥146.29 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥424.8 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥3,052.99 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,789.32 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,611.82 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,447.45 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥2,366.29 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 62.8% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 63.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 60.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 64.5% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 63.8% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 5.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 7.2% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 6.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 18.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 11,067 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 11,076 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 11,322 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 11,237 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 10,998 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥367.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥359.9bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥417.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥345.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥459.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥23.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | −¥3.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥24.5bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥206m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥14.1bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.4bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥120.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥26.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.5bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥20.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥30.5bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥6.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥7.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥118.1bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥743.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥742.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥822.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥746.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥779.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥313.7bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥287.6bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥430.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥454.5bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥465.9bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥507.0bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥544.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥34.5bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥31.3bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥70.82 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥106.43 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.51 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.59 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥412.3 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥70.82 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥106.43 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥23.51 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.59 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥412.1 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥160 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥160 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,499.91 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,584.92 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,625.06 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,768.5 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,898.56 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 57.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.8% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.3% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.1% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 296,566,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 296,566,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 296,566,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 296,566,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 296,566,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,984 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 3,043 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,034 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 3,005 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 2,953 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 579 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥50.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥40.2bn |
| Americasreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥232.4bn |
| Americasreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥147.2bn |
| Asia And Latin Americareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥54.2bn |
| Asia And Latin Americareportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥24.0bn |
| Chinareportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥111.9bn |
| Chinareportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥57.7bn |
| EMEAreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥76.0bn |
| EMEAreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥42.0bn |
| Japanreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥216.9bn |
| Japanreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥72.8bn |
| —segment total | employees | at 2024-03-31 | 10488 pure |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥691.5bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥343.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥741.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥383.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥60.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥48.5bn |
| Americasreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥212.7bn |
| Americasreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥133.4bn |
| Asia And Latin Americareportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥49.8bn |
| Asia And Latin Americareportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥22.1bn |
| Chinareportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥110.8bn |
| Chinareportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥55.6bn |
| EMEAreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥72.2bn |
| EMEAreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥41.6bn |
| Japanreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥238.9bn |
| Japanreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥72.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥684.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥325.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥744.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥374.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,107
| Item | Context | Value | Unit |
|---|---|---|---|
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)・医療用医薬品販売事業等における取引関係の強化のため保有しています。・定量的な保有効果を検証しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)・医療用医薬品販売事業等における取引関係の強化のため保有していましたが、2023年度に全株式を売却しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)アステナホールディングス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)・医療用医薬品販売事業等における取引関係の強化のため保有しています。・定量的な保有効果を検証しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)・医療用医薬品販売事業等における取引関係の強化のため保有しています。・定量的な保有効果を検証しています。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱メディパルホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)参天製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)㈱インテージホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)日本光電工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)㈱日清製粉グループ本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)久光製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes deemed holdings of shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Footnotes deemed holdings of shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row2Member | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しています。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc and internal system to prepare consolidated financial statements etc fairly in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Consolidated statement of profit or loss IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of financial position IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity IFRS (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes reporting entity consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes basis of preparation consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting estimates and judgements consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Notes segment information consolidated financial statements IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about products and services IFRS (text) | CurrentYearDuration | Text · Plus | |
| Information about major customers IFRS (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |